Innate Pharma S.A.

Innate Pharma S.A.

IPHYF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$141.7M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Innate Pharma S.A.Innate Pharma S.A.-2.4-231%--0.3
$-0.14

Current Fair Value

109.6% downside

Overvalued by 109.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$141.70 Million
Enterprise Value$146.07 Million
Earnings per Share$-0.55
Beta0.86
Outstanding Shares93,826,793

Return

Return on Equity231.07%ROE
Return on Assets-269.55%
Return on Invested Capital-5416.42%

Valuation & Multiples

P/E Ratio-2.35P/E Ratio
PEG34.47PEG
Price to Sales-Price to Sales
Price to Book Ratio-1.51Price to Book Ratio
Enterprise Value to Revenue15.54
Enterprise Value to EBIT-1.44
Enterprise Value to Net Income-2
Total Debt to Enterprise0.07
Debt to Equity-0.27Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
-$0.24
Est. -$0.29
Revenue
$6.47 M
Est. $6.28 M

Next Earnings Call

Expected Date
March 25, 2027
EPS Estimate
-$0.24
Consensus analyst estimate
Revenue Estimate
$2.74 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Innate Pharma

244 employees
CEO: Mondher Mahjoubi

Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company...